CD274 and neoplasm: Considering the fact that the CLP002 peptide was screened against human PD-L1 protein, which only exhibits 76% sequence identity with mouse PD-L1 protein, the antitumor activity of the CLP002 peptide in a mouse model implanted with mouse tumor cells is remarkable.